Eli Lilly buys Waltham biotech for $3.2B
By Hannah Green Eli Lilly and Co. is buying a Waltham biotech in a deal valued at around $3.2 billion. The startup being acquired is Morphic Holding Inc. (NASDAQ: MORF), a Waltham company working on treatments for chronic diseases such as types of inflammatory bowel disease. Indianapolis-based Lilly (NYSE: LLY) plans to acquire all outstanding shares of […]
